Humana · Letermovir · US health-plan appeal rights

Letermovir denied as duplicate or overlapping therapy by Humana?

Q: How long do I have to appeal a Humana Letermovir denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

Indications per FDA label: (1) HSCT CMV-seropositive adult recipients (Nov 2017 original); (2) high-risk D+/R- adult kidney transplant recipients (Jun 6, 2023 expanded label). 480 mg PO/IV daily (or 240 mg with cyclosporine). Duration up to 200 days post-tx per label.

Source policy: Humana Letermovir (Prevymis) Prior Authorization for CMV Prophylaxis

What works in the appeal

FDA label was EXPANDED Jun 6, 2023 to include adult kidney transplant recipients at high risk for CMV (D+/R- serostatus mismatch) for prophylaxis up to 200 days post-tx. Pivotal data: Limaye Chemaly et al. NEJM 2023 — letermovir non-inferior to valganciclovir for clinically significant CMV infection at week 52 (10.4% vs 11.8%) with significantly LESS myelosuppression (leukopenia 26% vs 64%) — critical advantage in transplant recipients on MMF/MPA. AST IDCOP CMV consensus (Razonable Clin Transplant 2019) + ISHLT 2018/2023 endorse extended prophylaxis in high-risk D+/R- kidney recipients. Document D+/R- serostatus + post-tx day.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other denial reasons for Humana Letermovir

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.